Severe COVID-19 Risk Up With Existing Health Conditions in US
Most commonly reported underlying health conditions were diabetes, chronic lung disease, CVD.
Diabetes
DIABETES
Dapagliflozin CKD Trial Stopped Early Due to “Overwhelming Efficacy”
The decision to stop the trial was made based on positive efficacy data following a recommendation from the study’s independent DMC.
Update for SGLT2 Inhibitors: Temporary Discontinuation Prior to Surgery Recommended
The FDA has approved safety labeling changes for sodium glucose co-transporter-2 (SGLT2) inhibitors. These include canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin.
CDC Updates Guidance on Evaluating, Testing for COVID-19 as More Tests Become Available
The Centers for Disease Control and Prevention has updated the guidance for evaluation of persons under investigation for coronavirus disease 2019 (COVID-19), expanding the criteria to a wider group of symptomatic patients.
Apabetalone Gets Breakthrough Tx Designation for MACE Prevention
The FDA has granted Breakthrough Therapy designation to apabetalone (Resverlogix Corp) in combination with standard of care therapy, including high-intensity statins, for the secondary prevention of major adverse cardiac events (MACE) in patients with type 2 diabetes mellitus and recent acute coronary syndrome.
Trulicity Approved to Reduce Risk of Major Adverse Cardiovascular Events
The FDA has approved Trulicity (dulaglutide; Lilly) to reduce the risk of major adverse cardiovascular events (MACE; cardiovascular death, nonfatal myocardial infarction [MI], or nonfatal stroke) in adults with type 2 diabetes mellitus who have established cardiovascular disease or multiple cardiovascular risk factors.
HbA1c Levels Lower in Older, Multimorbid Patients With T2DM
Patients with higher comorbidity burden more likely to be treated with insulin for T2DM.
Sodium-Glucose Cotransporter 2 Inhibitors Protect the Heart
Findings show benefit for cardiovascular disease in patients with type 2 diabetes regardless of kidney function.
Genetic Basis for Testosterone Levels Differs According to Sex
Genetically higher testosterone level generally benefits men, harms women in metabolic diseases.
Cardiovascular, Renal Outcomes Assessed in Older T2D Patients Treated With Linagliptin
Linagliptin was not associated with an increased risk of adverse cardiovascular (CV) events, renal events or hypoglycemia in older patients with type 2 diabetes, according to subgroup analysis from the phase 4 Carmelina® trial.
Want to read more?
Please login or register first to view this content.
Next post in Diabetes
